Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Conformational, Curative Ratiotherapy For Prostate Cancer (NO, N-): Phase III Multicenter Study Of The Contribution To Survival Without Clinical Or Biological Change With A Dose Variation Of 15% (80 Gy VS 70 Gy)

NCT00010244 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT00010244
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00010244 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Conformational, Curative Ratiotherapy For Prostate Cancer (NO, N-): Phase III Multicenter Study Of The Contribution To Survival Without Clinical Or Biological Change With A Dose Variation Of 15% (80 Gy VS 70 Gy)
Lead sponsor
UNICANCER
Phase
Phase 3
Overall status
Completed
Start date
September 30, 1999
Completion date
March 31, 2018
Enrollment
306 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer